ArticleFrontiers in immunology2025
Overlap syndrome of anti-aquaporin-4 positive neuromyelitis optica spectrum disorder and mixed connective tissue disease: a case report.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuromyelitis optica spectrum disorder (NMOSD) is an immune-mediated inflammatory demyelinating disease affecting the optic nerve and spinal cord. NMOSD frequently coexists with other autoimmune diseases. However, its concurrence with mixed connective tissue disease (MCTD) is rather rare and often overlooked. This study reports the first case in China of aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive NMOSD preceding MCTD with long-term follow-up. Between 2016 and 2024, the patient successively developed left lower limb numbness, hiccups, vomiting, facial numbness, Raynaud's phenomenon, finger swelling, digital sclerosis, and synovitis. Acute-phase management involved pulse steroid therapy, while remission maintenance utilized azathioprine, mycophenolate mofetil, rituximab, and inebilizumab for relapse prevention. This paper presents this case and reviews other cases of NMOSD combined with MCTD, aiming to contribute to the clinical understanding and management of this rare condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.